Start here if you're new
what it is
Gain Therapeutics is trying to turn one drug and one discovery platform into treatments for brain and metabolic diseases.
how it gets paid
Last year Gain Therapeutics made $100K in revenue. GT-02287 Parkinson's program was the main engine at $0M, or 40% of sales.
what just happened
The latest quarter brought in $305K of revenue and -$0.50 EPS.
At a glance
C++ balance sheet — some cracks in the foundation
-$0.89 fy2024 eps est
$0M fy2023 rev est
1.5 beta
~$93M market cap
xvary composite: 41/100 — below average
What they do
Gain Therapeutics is trying to turn one drug and one discovery platform into treatments for brain and metabolic diseases.
You are not buying a sales machine. You are buying a 72-person Phase 1 safety readout and a platform that hunts hidden control spots on proteins. That matters because your upside comes from 4 therapy areas, not just one shot at Parkinson's disease.
How they make money
$100K
annual revenue
GT-02287 Parkinson's program
$0M
CNS disorders pipeline
$0M
Lysosomal storage pipeline
$0M
Metabolic disorders pipeline
$0M
Oncology and other programs
$0M
The products that matter
Parkinson's disease drug development
GT-02287
$100K reported revenue base
this is the whole story. GT-02287 is the company's only clinical-stage asset, and interim Phase 1b analysis is scheduled for presentation at AD/PDTM 2026 in March. one asset carrying a $93M market cap is concentration risk in its purest form.
phase 1b/2
Key numbers
$93M
market cap
You are paying $93M for a company with no meaningful sales base.
$305K
quarterly revenue
That is the latest quarter's revenue. It is too small to fund much on its own.
72
trial patients
The lead drug's safety story rests on 72 people, not a large late-stage trial.
$0M
long-term debt
No debt helps, but it does not replace sales or reduce clinical risk.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 3 — safer than 50% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for GANX right now.
source: institutional data · return history unavailable
What just happened
missed estimates
The latest quarter brought in $305K of revenue and -$0.50 EPS.
Revenue was up 190% from the same quarter last year, but the base was still tiny. The company is still a funding story, not a sales story.
$0.3M
revenue
$0.50
eps
n/a
n/a
revenue base
$305K is the number that matters because it shows how little sales cushion the company has.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is GT-02287 failing to produce credible Parkinson's data.
med
single-asset failure
GANX is built around one clinical-stage program. If GT-02287 misses, the investment case does not get weaker — it mostly disappears.
A failed readout would hit the asset supporting essentially all of a $93M market cap.
med
cash burn and dilution
The company generated $0 in revenue, reported a $7.6M net loss in Q3 2025, and previously raised $12.3M through an ATM facility. That is not a durable funding model. It is a temporary bridge.
If losses stay near current levels, the $14.2M cash balance leaves little room for a slow regulatory path.
med
Phase 2 timing slips
GANX is awaiting FDA feedback tied to Phase 2. Biotech timelines rarely get shorter, and every delay matters more when there is no commercial revenue underneath the pipeline.
Delay pushes the value inflection point out while financing risk moves closer.
all three risks point to the same conclusion: this stock is not being valued on operating results. it is being valued on whether one program advances before the cash story takes over.
source: institutional data · regulatory filings · risk analysis
Pay attention to
catalyst
AD/PDTM 2026 in March
Interim Phase 1b analysis for GT-02287 is scheduled for presentation there. For a company with $0 revenue, this is the event that matters most.
regulatory
FDA feedback on Phase 2
Watch the timing and language around the IND response. A delay is not just annoying here — it affects funding pressure directly.
balance sheet
cash versus quarterly loss
$14.2M of cash next to a $7.6M quarterly net loss is the contrast to watch. You do not need a complex model to see why runway matters.
consensus
the $7.75 average price target
That target implies large upside from $1.79, but thin coverage makes biotech targets more sentiment marker than valuation anchor. Treat it as aspiration, not proof.
Analyst rankings
coverage
thin
GANX does not have the kind of broad sell-side coverage that gives consensus numbers a lot of statistical weight.
street view
$7.75
Average one-year price target. In human-speak, analysts see optionality if the trial works — not a stable earnings base they can underwrite with confidence.
signal quality
low
For small biotech names, clinical data usually matters more than ranking systems. The next readout will do more than any rating change.
source: institutional data
Institutional activity
institutional ownership data for GANX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$2
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive